» Articles » PMID: 34054949

Recurrence Factors and Characteristic Trends of Papillary Thyroid Cancer over Three Decades

Abstract

Background: The prevalence of thyroid cancer is rising worldwide. Although thyroid cancer has a favorable prognosis, up to 20% of patients experienced recurrent disease during the follow-up period. The present study aimed to examine the trend of incidence and factors associated with recurrence and outcomes of papillary thyroid cancer (PTC) in Thai patients over the last 30 years.

Methods: We reviewed the clinical data of all patients with PTC who were treated between 1987 and 2019 at Theptarin Hospital. Clinical characteristics, epidemic trend, factors associated with the persistence/recurrence of the disease, overall disease-specific survival rate, and overall disease-free survival rate were analysed.

Results: A total of 235 patients with PTC who were registered between 1987 and 2019 were reviewed. The mean age was 42.5 ± 14.3 years, with a mean follow-up of 9.5 years. Papillary thyroid microcarcinoma (PTMC) was consistently increased and accounted for 21.4% (50/235) of total cases. The American Thyroid Association (ATA) risk stratification was high in 24% of all PTMCs in the last decade, and 16.0% of these patients experienced local recurrence during the follow-up period. Coexistence with Hashimoto's thyroiditis (HT) was found in one-fifth of the patients with PTC and was correlated with a low recurrence rate (HR: 0.16, =0.013). Only age ≥55 years associated with the persistence/recurrence of the disease. The overall disease-free survival and disease-specific survival rates were 77.4% and 98.3%, respectively.

Conclusions: The prognosis of PTC is generally considered favorable. However, approximately one-fourth of patients with PTMC demonstrated more aggressive clinical behavior, particularly in the last decade of the study. Coexistence of HT contributed to a better prognosis.

Citing Articles

Selenium in cancer management: exploring the therapeutic potential.

He L, Zhang L, Peng Y, He Z Front Oncol. 2025; 14():1490740.

PMID: 39839762 PMC: 11746096. DOI: 10.3389/fonc.2024.1490740.


BRAF regulates circPSD3/miR-526b/RAP2A axis to hinder papillary thyroid carcinoma progression.

Li C, Zhao X, Zhao J, Zhao J, An L, Wu G BMC Mol Cell Biol. 2025; 26(1):6.

PMID: 39838328 PMC: 11753155. DOI: 10.1186/s12860-024-00528-2.


Comprehensive analysis of clinicopathologic and prognostic features in locally advanced thyroid papillary cancer.

Jiwang L, Dongman Y, Fengqin F, Yuejiao Z Braz J Otorhinolaryngol. 2025; 91(2):101553.

PMID: 39753045 PMC: 11753965. DOI: 10.1016/j.bjorl.2024.101553.


Ablation of Primary and Recurrent Thyroid Cancer: Current and Future Perspectives.

Freeman T, Pena O, Sag A, Young S Semin Intervent Radiol. 2024; 41(2):105-112.

PMID: 38993600 PMC: 11236443. DOI: 10.1055/s-0044-1786537.


Nomogram to predict the risk of biochemical recurrence and structural recurrence in patients with stage cN1 papillary thyroid carcinoma.

Ma T, Shi P, Ma T, Liang M, Wang L, Shi Y J Cancer Res Clin Oncol. 2023; 149(13):11073-11083.

PMID: 37340187 DOI: 10.1007/s00432-023-04998-3.


References
1.
Zhang C, Li Y, Li J, Chen X . Total thyroidectomy versus lobectomy for papillary thyroid cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2020; 99(6):e19073. PMC: 7015547. DOI: 10.1097/MD.0000000000019073. View

2.
Randolph G, Duh Q, Heller K, LiVolsi V, Mandel S, Steward D . The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012; 22(11):1144-52. DOI: 10.1089/thy.2012.0043. View

3.
Shah B, Griffiths R, Hall S . Thyroid cancer incidence among Asian immigrants to Ontario, Canada: A population-based cohort study. Cancer. 2017; 123(17):3320-3325. DOI: 10.1002/cncr.30746. View

4.
Graceffa G, Patrone R, Vieni S, Campanella S, Calamia S, Laise I . Association between Hashimoto's thyroiditis and papillary thyroid carcinoma: a retrospective analysis of 305 patients. BMC Endocr Disord. 2019; 19(Suppl 1):26. PMC: 6541562. DOI: 10.1186/s12902-019-0351-x. View

5.
Hay I . Management of patients with low-risk papillary thyroid carcinoma. Endocr Pract. 2007; 13(5):521-33. DOI: 10.4158/EP.13.5.521. View